Efficacy and Safety of Trastuzumab Deruxtecan and Nivolumab as Third- or Later-Line Treatment for HER2-Positive Advanced Gastric Cancer: A Single-Institution Retrospective Study-Reference-Cited by-同舟云学术

Efficacy and Safety of Trastuzumab Deruxtecan and Nivolumab as Third- or Later-Line Treatment for HER2-Positive Advanced Gastric Cancer: A Single-Institution Retrospective Study

Published:2023 Issue:4 Volume:23 Page:609
ISSN:2093-582X
Container-title:Journal of Gastric Cancer
language:en
Short-container-title:J Gastric Cancer

Author:

Shimozaki Keitaro¹²³^ORCID,Nakayama Izuma¹^ORCID,Takahari Daisuke¹^ORCID,Nagashima Kengo⁴^ORCID,Yoshino Koichiro¹^ORCID,Fukuda Koshiro¹^ORCID,Fukuoka Shota¹^ORCID,Osumi Hiroki¹^ORCID,Ogura Mariko¹^ORCID,Wakatsuki Takeru¹^ORCID,Ooki Akira¹^ORCID,Shinozaki Eiji¹^ORCID,Chin Keisho¹^ORCID,Yamaguchi Kensei¹^ORCID

Affiliation:

1. Department of Gastrointestinal Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

2. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

3. Department of Gastroenterology, Kawasaki Municipal Hospital, Kawasaki, Japan.

4. Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.

Publisher

XMLink

Subject

Cancer Research,Gastroenterology,Oncology

Link

https://jgc-online.org/pdf/10.5230/jgc.2023.23.e41

Reference23 articles.

1. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

2. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

3. Trastuzumab causes antibody-dependent cellular cytotoxicity–mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance

4. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

5. Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical complete response after trastuzumab deruxtecan 6th-line treatment for postoperative gastric cancer recurrence: a case report;Surgical Case Reports;2024-06-18

2. Nivolumab;Reactions Weekly;2024-02-17